Religion briefs for Sept. 19 | Community – Petoskey News-Review

Church to host food summit

PETOSKEY More than 6,500 people (11 percent) of Charlevoix and Emmet counties live at or below the poverty level.

In response to this need, dozens of churches and organizations host food pantries and/or offer free community meals throughout the week.

Emmanuel Episcopal Church, 1020 E. Mitchell St., Petoskey, is hosting a food summit from 9 a.m.-noon Saturday, Sept. 28, to bring individuals, churches and organizations together who are passionate about supporting people who are experiencing food insecurity to share best practices and learn about opportunities for collaboration.

Kim Baker, executive director of Manna Food Project, is the keynote speaker. Manna Food Project partners with food pantries, community meal programs and baby/paper pantries throughout Emmet, Charlevoix and Antrim counties.

In addition, there will be workshops on best practices in operating food pantries, community meals and grant writing.

Members of the community are invited to attend this summit, whether you are already involved in a food-based ministry or initiative, or if you would like to learn how you might become involved.

If you are interested in attending the summit or seeking more information, contact the Emmanuel Episcopal Church office at (231) 347-2350.

Community breakfast offered

ALANSON There will be a community breakfast from 9:30-10:45 a.m. Sunday, Sept. 22, at the Alanson Church of the Nazarene, 7489 Mission Road.

The meal is free of charge and features biscuits and gravy, scrambled eggs, waffles, juice and coffee.

There also will be face painting for the kids.

The breakfast is sponsored by the churchs Sunday School.

For more information, call the church at (231) 548-5462.

Stem cell therapies discussed

BOYNE CITY A discussion about stem cell therapies will begin at 6:30 p.m. Sunday, Sept. 22, at Lifetree Caf.

The program, Stem Cells: The Miracle Cure You May Be Missing Out On, includes a film featuring a regenerative stem cell procedure as well as an interview with Dr. Christopher Centeno, who performs orthopedic procedures using adult stem cells in both the U.S. and in an offshore clinic.

Over the next 20 to 30 years, many drugs we use today will be replaced by stem cells from our own bodies, or cells mass-produced in labs, said Centeno, who notes that the shift in medicine puts at risk much of the $300 billion prescription drug market.

Centeno, who uses stem cells as an alternative to joint replacement and to treat tendon, ligament and bone pain, wonders if concerns about lost revenue have prompted the domestic ban of some procedures that are available in other countries. This program provides insights into the ongoing debate.

The hourlong program is free of charge.

Lifetree Caf is in the First Presbyterian Church, 401 S. Park St. Use the Pine Street entrance.

Creation at Risk sermon topic

CHARLEVOIX Greensky Hill Indian United Methodist Church, 08484 Green Sky Hill Road, presents part four in the five-week series, The Season of Creation.

At 10 a.m., Sunday, Sept. 22, the Rev. Jonathan Mays will share a message from Jeremiah 8:18-9:1 entitled, Creation at Risk.

Mark the date for the finale of the series on Sunday, Sept. 29, when the community is invited to bring leashed or caged animals for The Blessing of the Animals ceremony at Greensky Hills outdoor worship space, The Tabernacle.

Also, Greensky Hills annual harvest dinner will be from 4-6:30 p.m., Saturday, Sept. 28, in Susan Hall.

All are welcome for a traditional menu including turkey, mashed potatoes and gravy, stuffing, squash, ham, corn, carrots, string beans, creamed cabbage, applesauce, tomatoes, dinner rolls, pie, coffee, tea and lemonade.

The cost is $12 for adults; $4 for children ages 4-12; and $35 for a family of six or more.

Message looks at anger, harsh words

CHARLEVOIX On Sunday, Sept. 22, the series, Braving the Wilderness, continues at Community Reformed Church.

The title of the message is Carried Anger and Harsh Words and will be based on Matthew 5:21-22.

Sunday morning services are at 8:30 and 10:15 with nursery available at each service.

Worship activities for children preschool through fourth grade are offered during the 10:15 service.

The church is located at 100 Oak St.

Read more:
Religion briefs for Sept. 19 | Community - Petoskey News-Review

Joseph M. Sanzari Childrens Hospital and John Theurer Cancer Center Launch Clinical Trial Evaluating Gene Therapy for Severe Sickle Cell Disease in…

MEDIA CONTACT

Available for logged-in reporters only

Newswise The Childrens Cancer Institute at the Joseph M. Sanzari Childrens Hospital at Hackensack Meridian Health Hackensack University Medical Center and the John Theurer Cancer Center have announced they are participating in a multicenter Phase I/II clinical trial of an investigational gene therapy from bluebird bio, Inc. This trial is specifically for adolescents and adults with severe sickle cell disease (SCD) who cannot be effectively treated using standard therapies such as antibiotics, vitamins, blood transfusions or any pain relieving medications. The study is evaluating the safety and effectiveness of LentiGlobin for sickle cell disease, a gene therapy produced using the patients own modified stem cells to treat their sickle cell disease.

By using the patients own cells to produce functional hemoglobin that can prevent sickling of their red blood cells, LentiGlobin for SCD offers patients the opportunity to treat their disease without the need to have a matched bone marrow donor. The John Theurer Cancer Center is one of a limited number of centers internationally, and the Joseph M. Sanzari Childrens Hospital is the only pediatric site in New Jersey, where the study, which is enrolling patients age 12-50, is taking place.

Sickle cell affects 100,000 Americans. It affects one in every 365 African American births and one in every 16,000 Hispanic American births, said Alfred P. Gillio, M.D., director, Childrens Cancer Institute and section chief, Pediatric Stem Cell Transplantation and Cellular Therapy Program, Joseph M. Sanzari Childrens Hospital at Hackensack University Medical Center. This trial is for patients who have severe sickle cell disease and seek advanced treatment options but do not have a well-matched stem cell donor. Only 15% of sickle cell patients have a matched sibling donor and only 25 percent of patients have a matched unrelated volunteer donor.

Sickle cell affects every organ in a patients body, said Stacey Rifkin-Zenenberg, D.O., FAAP, pediatric hematologist/oncologist, Childrens Cancer Institute, and section chief, Pain and Palliative Care, Joseph M. Sanzari Childrens Hospital at Hackensack University Medical Center. This disease really has a tremendous effect not only on the patient, but also the family.

Sickle cell disease is an inherited disease caused by a mutation in the beta-globin gene, resulting in abnormal hemoglobin and sickle-shaped red blood cells. Symptoms and complications of the disease include anemia, infections, stroke, poor quality of life and early death. To date, the only cure for sickle cell disease is receiving a stem cell transplant from a matched donor, but this is not a therapeutic option for many patients. Supportive care including hydroxyurea and blood transfusions can ameliorate symptoms of the disease. To date, without a marrow donor, there has been no alternate curative therapy. Life expectancy of a person with sickle cell disease is 20 to 40 years of age. In some cases, patients using disease modifying medications can live to 50 or 60.

This therapy may be a major advance for sickle cell patients and so far, the results look very promising, said Scott D. Rowley, M.D., FACP, hematologist, medical director, Stem Cell Transplantation and Cellular Therapy and medical director, BMT Cell Lab, John Theurer Cancer Center, Hackensack Meridian Health Hackensack University Medical Center, who is enrolling adult patients. This investigational treatment, which is a one-time therapy, may be an option for our patients who have no other treatment options.

The results from early clinical studies are encouraging, said Dr. Gillio. With this treatment, the patient is their own donor and we are modifying their own cells to add copies of a functional beta globin gene.

In the current study:

About Hackensack Meridian Health Hackensack University Medical Center

Hackensack Meridian Health Hackensack University Medical Center, a 781-bed nonprofit teaching and research hospital located in Bergen County, NJ, is the largest provider of inpatient and outpatient services in the state. Founded in 1888 as the countys first hospital, it is now part of the largest, most comprehensive and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research and life-enhancing care, which is comprised of 34,100 team members and more than 6,500 physicians. Hackensack University Medical Center is ranked #2 in New Jersey and #59 in the country in U.S. News & World Reports 2019-20 Best Hospital rankings and is ranked high-performing in the U.S. in colon cancer surgery,lung cancersurgery,COPD, heart failure, heart bypass surgery, aortic valve surgery,abdominal aortic aneurysm repair, knee replacement and hip replacement. Out of 4,500 hospitals evaluated, Hackensack is one of only 57 that received a top rating in all nine procedures and conditions. Hackensack University Medical Center is one of only five major academic medical centers in the nation to receive Healthgrades Americas 50 Best Hospitals Award for five or more years in a row. Beckers Hospital Review recognized Hackensack University Medical Center as one of the 100 Great Hospitals in America 2018. The medical center is one of the top 25 green hospitals in the country according to Practice Greenhealth, and received 26 Gold Seals of Approval by The Joint Commission more than any other hospital in the country. It was the first hospital in New Jersey and second in the nation to become a Magnet recognized hospital for nursing excellence; receiving its sixth consecutive designation in 2019. Hackensack University Medical Center has created an entire campus of award-winning care, including: John Theurer Cancer Center, a consortium member of the NCI-designated Georgetown Lombardi Comprehensive Cancer Center; the Heart & Vascular Hospital; and the Sarkis and Siran Gabrellian Womens and Childrens Pavilion, which houses the Joseph M. Sanzari Childrens Hospital and Donna A. Sanzari Womens Hospital, which was designed with The Deirdre Imus Environmental Health Center and listed on the Green Guides list of Top 10 Green Hospitals in the U.S. Hackensack University Medical Center is the Hometown Hospital of the New York Giants and the New York Red Bulls and is Official Medical Services Provider to THE NORTHERN TRUST PGA Golf Tournament. It remains committed to its community through fundraising and community events especially the Tackle Kids Cancer Campaign providing much needed research at the Childrens Cancer Institute housed at the Joseph M. Sanzari Childrens Hospital. To learn more, visit http://www.HackensackUMC.org.

Follow this link:
Joseph M. Sanzari Childrens Hospital and John Theurer Cancer Center Launch Clinical Trial Evaluating Gene Therapy for Severe Sickle Cell Disease in...

Engineering lymphatic vessels as a therapeutic to heal the heart – ND Newswire

Donny Hanjaya Putra and Adriana Archilla.

The cardiovascular system is a complex network of veins, arteries and capillaries. Within that network, lymphatic vessels are critical to the hearts ability to heal in the event of a heart attack. When theyre functional, lymphatic vessels drain excess fluid that can cause swelling, and carry immune cells that can regulate inflammation and fight infection each of which are a potential complication following a heart attack. And yet, lymphatic vessels have a history of being overlooked in cardiovascular research, becoming more prominent only in the last 10 years.

With funding from the American Heart Association, Donny Hanjaya-Putra, assistant professor in the Department of Aerospace and Mechanical Engineering and in the Bioengineering Graduate Program, as well as in the Department of Chemical and Biomolecular Engineering, will use biomaterials and stem cells to regenerate lymphatic vessels and study their potential for therapeutic applications.

After a heart attack there is an influx of inflammatory cells that can cause swelling, Hanjaya-Putra said. What you have is a wound healing process. We propose that if we can regenerate the lymphatic vessel, we may be able to tip the balance of those inflammatory cells, drain excess fluid and promote healing of the heart.

Earlier this year the American Heart Association reported heart disease as the No. 1 cause of death in the United States. The report also revealed an estimated 121.5 million adults close to half the population of the United States have some form of cardiovascular disease, such as high blood pressure.

For the study, Hanjaya-Putra will use adult and induced pluripotent stem cells, as well as biomaterials to create synthetic lymphatic vessels. If successful, he said, the bioengineered lymphatic vessels could be tested in similar applications to combat obesity and metabolic syndrome draining fluid buildup in the gut caused by fatty diets or reducing fluid and waste buildup in the brain, which has been linked to cognitive decline as seen in aging and Alzheimers disease.

Hanjaya-Putra received the American Heart Associations 2019 Career Development Award, which will fund the research. He is an affiliated member of Notre Dames Advanced Diagnostics and Therapeutics initiative, the Center for Nano Science and Technology, the Harper Cancer Research Institute and the Center for Stem Cells and Regenerative Medicine.

Contact: Jessica Sieff, assistant director of media relations, 574-631-3933, jsieff@nd.edu

See original here:
Engineering lymphatic vessels as a therapeutic to heal the heart - ND Newswire

SanBio Granted Regenerative Medicine Advanced Therapy Designation from the US FDA for SB623 for the Treatment of Chronic Neurological Motor Deficits…

Sept. 19, 2019 06:38 UTC

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- The SanBio Group (SanBio Co., Ltd. and SanBio, Inc.)(TOKYO:4592), a scientific leader in regenerative medicine for neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Designation for SB623 cell therapy for the treatment of chronic neurological motor deficits secondary to traumatic brain injury (TBI). The designation is based on clinical results of SB623 including the Phase 2 Study of Modified Stem Cells in Traumatic Brain Injury (STEMTRA) trial.

Created under the 21st Century Cures Act, the RMAT designation is reserved for a regenerative medicine therapy intended to treat, modify, reverse, or cure a serious condition, and clinical evidence indicates that the therapy has the potential to address unmet medical needs for such disease or condition. Similar to the Breakthrough Therapy designation, the RMAT designation offers sponsors of cell and gene therapies eligibility for expedited development and regulatory review of their product candidate, including earlier and more frequent consultation with the FDA, and the potential for Priority Review and Accelerated Approval.

The RMAT designation for SB623 is an important regulatory milestone for SanBio as we investigate it as a treatment option for patients with chronic neurological motor deficits resulting from a traumatic brain injury, said Bijan Nejadnik, M.D., Chief Medical Officer and Head of Research. TBIs are one of the most common health conditions worldwide that often cause long-term complications or death. We look forward to working with the FDA on a potentially accelerated clinical development program to address this serious unmet medical need.

The RMAT designation augments the Sakigake Designation for innovative medical products from the Ministry of Health, Labour, and Welfare of Japan.

About SB623 SB623 is a proprietary, cell-based investigational product made from modified and cultured adult bone marrow-derived mesenchymal stem cells that undergo temporary genetic modification. Implantation of SB623 cells into injured nerve tissue in the brain is expected to trigger the brains natural regenerative ability to recover lost motor functions.

SanBio expects to initiate a Phase 3 trial for SB623 for the treatment of chronic neurological motor deficits secondary to TBI by the end of the fiscal year ending January 31, 2021. SB623 is also currently in a Phase 2b clinical trial for treatment of chronic motor deficit resulting from ischemic stroke.

About the Study of Modified Stem Cells in Traumatic Brain Injury (STEMTRA) Trial STEMTRA was a 12-month, Phase 2, randomized, double-blind, surgical sham-controlled, global trial evaluating the efficacy and safety of SB623 compared to sham surgery in patients with stable chronic neurological motor deficits secondary to TBI. In this study, SB623 cells were implanted directly around the site of brain injury.

To be eligible for this trial, patients (ages 18-75) must have been at least 12 months post-TBI and had a Glasgow Outcome Scale extended (GOS-E) score of 3-6 (e.g., moderate or severe disability). Patients must also have been able to undergo all planned neurological assessments and had no seizures in the prior three months. The primary endpoint was mean change from baseline in Fugl-Meyer Motor Scale (FMMS) score which measures changes in motor impairment at six months. The STEMTRA trial enrolled 61 patients from 13 surgical and 18 assessment sites in the U.S., Japan and Ukraine.

In this study, SB623 met its primary endpoint, with patients treated with SB623 achieving an average 8.3 point improvement from baseline in the FMMS, versus 2.3 in the control group, at 24 weeks (p=0.040). Of patients treated with SB623, 18 (39.1%) reached a 10 or more point improvement of FMMS compared to one control patient (6.7%; p=0.039). No new safety signals were identified. The most commonly reported adverse event were headaches.

About SanBio Group (SanBio Co., Ltd. and SanBio, Inc.) SanBio Group is a regenerative medicine company with cell-based products focused on neurological disorders in various stages of research, development and clinical trials. The Companys lead asset, SB623, is currently being investigated for the treatment of several conditions including chronic neurological motor deficit resulting from ischemic stroke and traumatic brain injury. SanBio has received a Japanese marketing license for regenerative medicine products from the Tokyo Metropolitan Government, and plans to begin marketing regenerative medicine products in Japan by the end of the fiscal year ending January 31, 2021. The Company is headquartered in Tokyo, Japan and Mountain View, California, and additional information about SanBio Group is available at https://sanbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190918006094/en/

Link:
SanBio Granted Regenerative Medicine Advanced Therapy Designation from the US FDA for SB623 for the Treatment of Chronic Neurological Motor Deficits...

Stem Cell Therapies Market by Top Key Players, Size, Subdivision & Market Dynamics Forces – NewsVarsity

Stem cells are undifferentiated biological cells, and having remarkable potential to divide into any kind of other cells. When a stem cell divides, each new cell will be a new stem cell or it will be like another cell which is having specific function such as a muscle cell, a red blood cell, brain cell and some other cells.

There are two types of stem cells Embryonic cells Adult stem or Somatic cells

Stem cells harvested from umbilical cord blood just after birth. And this cells can be stored in specific conditions. Stem cells also can be harvest from bone marrow, adipose tissue.

Embryonic cells can differentiate into ectoderm, endoderm and mesoderm in developing stage. Stem cells used in the therapies and surgeries for regeneration of organisms or cells, tissues.

Stem cells are used for the treatment of Gastro intestine diseases, Metabolic diseases, Immune system diseases, Central Nervous System diseases, Cardiovascular diseases, Wounds and injuries, Eye diseases, Musculoskeletal disorders.

Harvesting of Adult cell is somewhat difficult compare to embryonic cells. Because Adult cells available in the own body and it is somewhat difficult to harvest.

Stem Cell Therapies Market: Drivers and Restraints

Technology advancements in healthcare now curing life threatening diseases and giving promising results. Stem Cell Therapies having so many advantages like regenerating the other cells and body organisms. This is the main driver for this market. These therapies are useful in many life threatening treatments. Increasing the prevalence rate of diseases are driven the Stem Cell Therapies market, it is also driven by increasing technology advancements in healthcare. Technological advancements in healthcare now saving the population from life threatening complications.

Get Sample Copy of this report at https://www.futuremarketinsights.com/reports/sample/rep-gb-1087?source=atm

Increasing funding from government, private organizations and increasing the Companies focus on Stem cell therapies are also driven this market

However, Collecting the Embryonic Stem cells are easy but Collecting Adult Stem cell or Somatic Stem cells are difficult and also we have to take more precautions for storing the collected stem cells.

Stem Cell Therapies Market: Segmentation

Stem Cell Therapies are segmented into following types

Based on treatment: Allogeneic stem cell therapy Autologous stem cell therapy

Based on application: Gastro intestine diseases Metabolic diseases Immune system diseases Central Nervous System diseases Cardiovascular diseases Wounds and injuries Eye diseases Musculoskeletal disorders

Based on End User: Hospitals Ambulatory Surgical centers

Stem Cell Therapies Market: Overview

With rapid technological advantage in healthcare and its promising results, the use of Stem Cell Therapies will increase and the market is expected to have a double digit growth in the forecast period (2015-2025).

Request to view TOC at https://www.futuremarketinsights.com/toc/rep-gb-1087?source=atm

Stem Cell Therapies Market: Region- wise Outlook

Depending on geographic regions, the global Stem Cell Therapies market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific excluding Japan, Japan and Middle East & Africa.

The use of Stem Cell Therapies is high in North America because it is highly developed region, having good technological advancements in healthcare setup and people are having good awareness about health care. In Asia pacific region china and India also having rapid growth in health care set up. Europe also having good growth in this market.

Stem Cell Therapies Market: Key Players

Some of the key players in this market are Mesoblast Ltd., Roslin Cells, Regeneus Ltd, ReNeuron Group plc, International Stem Cell Corporation.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on: Market Segments Market Dynamics Market Size Supply & Demand Current Trends/Issues/Challenges Competition & Companies involved Technology Value Chain

Regional analysis includes North America (U.S., Canada) Latin America (Mexico. Brazil) Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg) Eastern Europe (Poland, Russia) Asia Pacific (China, India, ASEAN, Australia & New Zealand) Japan Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights: Detailed overview of parent market Changing market dynamics in the industry In-depth market segmentation Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape Strategies of key players and products offered Potential and niche segments, geographical regions exhibiting promising growth A neutral perspective on market performance Must-have information for market players to sustain and enhance their market footprint.

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Customization for this report at https://www.futuremarketinsights.com/customization-available/rep-gb-1087?source=atm

Visit link:
Stem Cell Therapies Market by Top Key Players, Size, Subdivision & Market Dynamics Forces - NewsVarsity

Stem Cell Assay Market to Record an Exponential CAGR by 2025 – Wolf Mirror

Browse Full Report at https://www.persistencemarketresearch.com/market-research/stem-cell-assay-market

The undifferentiated biological cells that can differentiate into specialized cells are called as stem cells. In the human body during early life and growth phase, stem cells have the potential to develop into other different cell types. Stem cells can differ from other types of cells in the body. There are two types of stem cells namely the embryonic stem cells and adult stem cells. Adult stem cells comprise of hematopoietic, mammary, intestinal, neural, mesenchymal stem cells, etc. All stem cells have general properties such as capability to divide and renew themselves for long period. Stem cells are unspecialized and can form specialized cell types. The quantitative or qualitative evaluation of a stem cells for various characteristics can be done by a technique called as stem cell assay. The identification and properties of stem cells can be illustrated by using Stem Cell Assay. The new developments in the field of stem cell assay research related to the claim of stem cell plasticity have caused controversies related to technical issues. In the study of stem cell assay, most conflicting results arise when cells express stem cell characteristics in one assay but not in another. The most important factor is that the true potential of stem cells can only be assessed retrospectively. The retrospective approach refers to back drop analysis which provides quantitative or qualitative evaluation of stem cells. The development in embryonic & adult stem cells assay will be beneficial to the global stem cell assay market. Stem cell assays find applications in pharmaceutical & biotechnology companies, academic & research institutes, government healthcare institutions, contract research organizations (CROs) and others. The influential factors like chronic diseases, increased investment in research related activities, and technological advancements in pharmaceutical & biotech industry is anticipated to drive the growth of the global stem cell assay market during the forecast period. The cost of stem cell based therapies could be one of the major limiting factor for the growth of the global stem cell assay market.

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/13462?source=atm

The global stem cell assay market has been segmented on the basis of kit type, application, end user and region. The global stem cell assay market can be differentiated on the basis of kit type into human embryonic stem cell kits and adult stem cell kits. The adult stem cell kit includes hematopoietic stem cell kits, mesenchymal stem cell kits, induced pluripotent stem cell kits (IPSCs), and neuronal stem cell kits. The adult stem cell kits are projected to witness the highest CAGR during the forecast period due to the ease of use, cost & effectiveness of this type of kit in stem cell analysis.

Based on application global stem cell assay market is based on drug discovery and development, therapeutics and clinical research. The therapeutics segment includes oncology, dermatology, cardiovascular treatment, orthopedic & musculoskeletal spine treatment, central nervous system, diabetes and others.

Depending on geographic segmentation, the global stem cell assay market is segmented into five key regions: Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is expected to contribute significant share to the global stem cell assay market. The stem cell assay market in Europe, has gained impetus from the government & industrial initiatives for stem cell based research and the market in Europe is expected to grow at a remarkable pace during the forecast period. The major players in the global stem cell assay market include GE Healthcare, Promega Corporation, Thermo Fisher Scientific Inc., Merck KGaA, Cell Biolabs, Inc., Hemogenix Inc., Stemcell Technologies Inc., Bio-Rad Laboratories Inc., R&D Systems Inc., and Cellular Dynamics International Inc.

Get Full Report Access of this report at https://www.persistencemarketresearch.com/checkout/13462?source=atm

The rest is here:
Stem Cell Assay Market to Record an Exponential CAGR by 2025 - Wolf Mirror